Psoriasis patients undergoing biologic/other systemic therapies may experience mild SARS-CoV-2 infection A recent study published in the ‘Medicina’ Journal by the Multidisciplinary …
Our new identity
A Motivation towards Peptide Drug
Discovery and changing patients’ lives
Therapeutic Areas
Bringing the best of 25 years of peptide research and development
Dermatology is a specialised branch that deals with research, diagnosis and treatment of conditions associated with the skin.
Oncology is the branch of medicine that deals with research, identification, and treatment of cancer.
It is the field of medicine which deals with the study, diagnosis and treatment of diseases associated with the digestive system.
The WHO and UN have recognized four major musculoskeletal conditions contributing to a major burden on individuals and health care…
Our Brands
Over 2,000,000 scientist hours into new peptide drug development, ISSAR has touched 1,00,000 plus lives
Development Pipeline
Solving the unmet healthcare needs using novel peptide technology
Novoskin®
Vitiligo - Topical
Xylentra®
Wound care - Topical
IS -107
Solid tumors - Injectable
IS - 217
Soriacare®
Psoriasis - Injectable
Topical
ISSAR’S Pre-Clinical
Pipeline
INDIA
INDIA
US FDA
INDIA
US FDA
IBD (Injectable)
Sepsis (Injectable)
Rheumatoid Arthritis
Atopic Dermatitis
Key Milestones
A Motivation towards Peptide Drug Discovery and changing patients’ lives
0
Products Commercialized
0
Patents - Granted
0
+
Drugs In Pipeline -Life To New Drugs
0
Lives Touched -Giving Hope to Lives
About Us
Formed as a company driven by pharmaceutical innovation to address the unmet healthcare needs, ISSAR pharmaceuticals Pvt. Ltd. was founded in 1995 by Mr Ramakrishna Isanaka.
Featured Article
CXCL9: A biomarker for Vitiligo activity A recent study published in the ‘Nature’ scientific journal, proposed that the CXCL9 gene is a …
Rheumatoid Arthritis (RA) In a Global Burden of Disease (GBD) study conducted in the year 2010, which studied 291 conditions, Rheumatoid Arthritis …
In The News
Dr Reddy’s Laboratories Ltd (DRL) to emerge as one of the top five dermatology companies in India with their recent launch of Melgain licensed by ISSAR PHARMACEUTICALS
Contact Us
